Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04381468 · ClinicalTrials.gov registry record · Phase 1
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
A Phase 1 study, sponsored by Vaccinex.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT04381468 is a Phase 1 study that has completed, run by Vaccinex. The registered enrollment target is 50 participants.
The verdict
NCT04381468, a Phase 1 study, has completed, sponsored by Vaccinex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.
Interventions
- DRUG Placebo
- DRUG Pepinemab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-07-22 |
| Est. Completion | 2024-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04381468
The ClinicalTrials.gov registry entry for NCT04381468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vaccinex, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04381468 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04381468 about?
NCT04381468 is a clinical study titled "SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)". To investigate safety, tolerability, the effects on cognition and brain metabolism of pepinemab in early AD dementia (early AD) subjects.
What is the current status of trial NCT04381468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2021-07-22. Estimated completion is 2024-06-05.
What interventions are being tested in trial NCT04381468?
The interventions under investigation include: Placebo (DRUG), Pepinemab (DRUG).
Who is sponsoring clinical trial NCT04381468?
This trial is sponsored by Vaccinex, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.